基因工程益生菌在炎症性肠病中的研究进展  

Research Progress of Genetically Engineered Probiotics in Inflammatory Bowel Disease

作　　者：赵菊阳 陈曦 李丽梅[2] 王新一 吕梦圆 ZHAO Juyang;CHEN Xi;LI Limei;WANG Xinyi;LV Mengyuan(College of Life and Health,Dalian University,Dalian 116622,China;College of Science,Shenyang Agricultural University,Shenyang 110866,China)

机构地区：[1]大连大学生命健康学院,辽宁大连116622 [2]沈阳农业大学理学院,辽宁沈阳110866

出　　处：《工业微生物》2024年第4期22-24,共3页Industrial Microbiology

基　　金：2022年度大连大学学科建设专项-学科交叉项目“重点类”“基于RPA/CRISPR/Cas9突变富集技术构建循环肿瘤DNA纳米生物传感新方法及其应用研究”(编号:DLUXK-2022-ZD-002)。

摘　　要：炎症性肠病(Inflammatory Bowel Disease,IBD)是一种慢性且易反复发作的肠道炎症性疾病。当前对其治疗方法存在临床缓解率低、复发率高和副作用明显等问题,因此,开发新型的高效治疗策略成为了该领域的全球性目标。工程益生菌疗法作为IBD领域的前沿疗法之一,为突破IBD治疗瓶颈带来了新的可能。文章对设计与构建基因工程益生菌过程中涉及的基础问题进行了概述,并总结了工程益生菌在IBD诊断和临床治疗中的应用,以期为IBD临床诊疗提供新的视角和思路。Inflammatory Bowel Disease(IBD)is a chronic and recurrent inflammatory disease of the bowel.The current treatment methods have some problems such as low clinical remission rate,high recurrence rate and obvious side effects,so the development of novel and efficient treatment strategies has become a global goal in this field.As one of the emerging therapies in the field of IBD,engineered probiotic therapy brings new possibilities for breaking through the bottleneck of IBD treatment.This article describes the basic problems involved in the design and construction of genetically engineered probiotics,and summarizes the application of engineered probiotics in the diagnosis and clinical treatment of IBD,in order to provide new perspectives and ideas for the clinical diagnosis and treatment of IBD.

关 键 词：益生菌 炎症性肠病 合成生物学 基因工程 

分 类 号：R574[医药卫生—消化系统]